Medical device and MedTech insights, news, tips and more

OpSens Announces Closing of $28.75 Million Bought Deal Public Offering Including $3.75 Million Over-Allotment Option Exercised in Full

February 28, 2021


OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announced last week the closing of its previously announced bought deal public offering (the “Offering”) of common shares of the Company (the “Common Shares”), for total gross proceeds of approximately $28,750,000. The Company issued an aggregate of 15,972,222 Common Shares, at a price of $1.80 per Common Share, including 2,083,333 Common Shares issued pursuant to the exercise in full of the underwriters’ over-allotment option.

The Offering was conducted by a syndicate of underwriters led by Stifel GMP as sole bookrunner and lead underwriter, and including Paradigm Capital Inc., Raymond James Ltd., RBC Dominion Securities Inc., and M Partners Inc.

The Company intends to use the net proceeds of the Offering (i) to execute its commercialization and marketing strategy, (ii) to fund research and product development, (iii) to secure additional manufacturing capacity for its coronary artery stenosis products, its structural heart products, its fiber optic sensors and signal conditioners and, (iv) for general working capital purposes.

The Common Shares were offered by way of a short form prospectus dated February 19, 2021 and filed in all of the provinces of Canada pursuant to Regulation 44-101 respecting Short Form Prospectus Distributions (National Instrument 44-Short Form Prospectus Distributions outside of Québec) and in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About OpSens Inc. ( or )

OpSens focuses mainly on coronary artery stenosis measurement in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

See Full Press Release at the Source: OpSens: Closing of $28.75 M Bought Deal Public Offering – Including $3.75 M Over-Allotment Option Exercised in Full – Opsens

Press Release by: OpSens

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.